Maria Natalia Gandur Quiroga: Erdafitinib showcased its potential in a phase 3 trial

Maria Natalia Gandur Quiroga shared on LinkedIn:

“Title: Advancements in Urothelial Carcinoma Treatment: Erdafitinib Outshines Chemotherapy

1) Introduction:
In the dynamic landscape of cancer therapeutics, a recent breakthrough has emerged in the treatment of advanced urothelial carcinoma. Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) inhibitor, has demonstrated remarkable efficacy, particularly in patients with FGFR3/2 alterations. This article delves into the key findings of a global phase 3 trial, shedding light on Erdafitinib’s superiority over traditional chemotherapy.

2) Key Messages and Results:
Erdafitinib, approved for locally advanced or metastatic urothelial carcinoma post-platinum-containing chemotherapy, showcased its potential in a phase 3 trial. The study, comparing Erdafitinib to chemotherapy in patients with FGFR-altered metastatic urothelial carcinoma, delivered compelling results.

3) Overall Survival: Erdafitinib exhibited a significantly longer median overall survival (12.1 months vs. 7.8 months) compared to chemotherapy.
Progression-Free Survival: The median progression-free survival with Erdafitinib (5.6 months) surpassed that of chemotherapy (2.7 months).
Safety Profile: Erdafitinib demonstrated a safety profile comparable to chemotherapy, with fewer treatment-related deaths (0.7% vs. 5.4%).

4) Implications and Conclusions:
The clinical benefit of Erdafitinib is particularly pronounced in patients with FGFR alterations post anti-PD-1 or anti-PD-L1 treatment. These findings underscore the importance of molecular testing to identify patients who can benefit from Erdafitinib.”

For the article click here.
Source: Maria Natalia Gandur Quiroga/LinkedIn

Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Instituto de Oncología Ángel H. Roffo in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors.  She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.